SG11202111162PA - Pyridin-3-yl derivatives - Google Patents

Pyridin-3-yl derivatives

Info

Publication number
SG11202111162PA
SG11202111162PA SG11202111162PA SG11202111162PA SG11202111162PA SG 11202111162P A SG11202111162P A SG 11202111162PA SG 11202111162P A SG11202111162P A SG 11202111162PA SG 11202111162P A SG11202111162P A SG 11202111162PA SG 11202111162P A SG11202111162P A SG 11202111162PA
Authority
SG
Singapore
Prior art keywords
alkylene
chloro
methoxypyridin
isopropylphenyl
carboxamide
Prior art date
Application number
SG11202111162PA
Other languages
English (en)
Inventor
Martin Bolli
Christine Brotschi
Cyrille Lescop
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of SG11202111162PA publication Critical patent/SG11202111162PA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Debugging And Monitoring (AREA)
SG11202111162PA 2019-06-18 2020-06-17 Pyridin-3-yl derivatives SG11202111162PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2019065963 2019-06-18
PCT/EP2020/066767 WO2020254408A1 (en) 2019-06-18 2020-06-17 Pyridin-3-yl derivatives

Publications (1)

Publication Number Publication Date
SG11202111162PA true SG11202111162PA (en) 2021-11-29

Family

ID=71105482

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202111162PA SG11202111162PA (en) 2019-06-18 2020-06-17 Pyridin-3-yl derivatives

Country Status (18)

Country Link
US (1) US12479820B2 (https=)
EP (1) EP3986884A1 (https=)
JP (1) JP7494222B2 (https=)
KR (1) KR102786045B1 (https=)
CN (1) CN114026082B (https=)
AR (1) AR119162A1 (https=)
AU (1) AU2020298014B2 (https=)
BR (1) BR112021025236A2 (https=)
CA (1) CA3143618A1 (https=)
CL (1) CL2021003348A1 (https=)
IL (1) IL288950B2 (https=)
MA (1) MA56504A (https=)
MX (1) MX2021015727A (https=)
PH (1) PH12021553178A1 (https=)
SG (1) SG11202111162PA (https=)
TW (1) TWI845708B (https=)
UA (1) UA130692C2 (https=)
WO (1) WO2020254408A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3802517T (pt) 2018-06-07 2023-03-20 Idorsia Pharmaceuticals Ltd Derivados de piridinilo substituídos por alcoxi como antagonistas do recetor de lpa1 e a sua utilização no tratamento da fibrose
JP7665619B2 (ja) 2019-12-04 2025-04-21 イドルシア・ファーマシューティカルズ・リミテッド 線維性疾患の治療に使用するためのアゼチジンlpa1受容体アンタゴニストのピルフェニドン及び/又はニンテダニブとの合剤
WO2025169931A1 (ja) * 2024-02-05 2025-08-14 Ube株式会社 カルボキサミド化合物

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL130088C (https=) 1960-03-14
WO1994006802A1 (fr) * 1992-09-18 1994-03-31 Yoshitomi Pharmaceutical Industries, Ltd. Compose de thienodiazepine et son utilisation medicinale
GB9420763D0 (en) 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
GB9919776D0 (en) 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
AU7961300A (en) 1999-10-29 2001-05-14 Yamanouchi Pharmaceutical Co., Ltd. Kainic acid neurocytotoxicity inhibitors
AU2001262185A1 (en) 2000-04-10 2001-10-23 Novartis Ag Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion
WO2002062389A1 (en) 2001-02-08 2002-08-15 Ono Pharmaceutical Co., Ltd. Remedies for urinary diseases comprising lpa receptor controlling agents
US7435824B2 (en) 2002-04-19 2008-10-14 Bristol-Myers Squibb Company Prodrugs of potassium channel inhibitors
TW200403058A (en) 2002-04-19 2004-03-01 Bristol Myers Squibb Co Heterocyclo inhibitors of potassium channel function
TW200505902A (en) 2003-03-20 2005-02-16 Schering Corp Cannabinoid receptor ligands
WO2004110350A2 (en) 2003-05-14 2004-12-23 Torreypines Therapeutics, Inc. Compouds and uses thereof in modulating amyloid beta
WO2005023761A2 (en) 2003-09-11 2005-03-17 Kemia, Inc. Cytokine inhibitors
JPWO2005037269A1 (ja) 2003-10-21 2006-12-28 住友製薬株式会社 新規ピペリジン誘導体
EP1684759A4 (en) 2003-11-12 2009-06-10 Merck & Co Inc 4-phenyl-piperidinosulfonyl-Glycine-TRANSPORTER INHIBITORS
EP1687296A1 (en) 2003-11-18 2006-08-09 Warner-Lambert Company LLC Antibacterial aminoquinazolidinedione derivatives
WO2006091862A2 (en) 2005-02-24 2006-08-31 Kemia, Inc. Cytokine inhibitors and their use in therapy
CN101198590B (zh) 2005-08-24 2012-05-09 卫材R&D管理有限公司 吡啶衍生物及嘧啶衍生物(3)
WO2007058990A2 (en) 2005-11-14 2007-05-24 Kemia, Inc. Therapy using cytokine inhibitors
CA2691214A1 (en) 2006-06-09 2007-12-21 Kemia, Inc. Therapy using cytokine inhibitors
JP5164510B2 (ja) 2006-10-06 2013-03-21 日本曹達株式会社 含窒素複素環化合物および有害生物防除剤
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
EP2212322B1 (en) 2007-10-18 2012-04-04 Merck Sharp & Dohme Corp. Quinolizidinone m1 receptor positive allosteric modulators
AU2009239500B2 (en) 2008-04-21 2014-01-30 Lexicon Pharmaceuticals, Inc. LIMK2 inhibitors, compositions comprising them, and methods of their use
PT2303270T (pt) 2008-05-05 2017-08-25 Sanofi Sa Derivados fundidos do ácido ciclopentanocarboxílico substituídos por acilamino e sua utilização como produtos farmacêuticos
UY32072A (es) 2008-08-26 2010-03-26 Boehringer Ingelheim Int Tienopirimidinas para composiciones farmacéuticas
KR101678255B1 (ko) * 2009-09-25 2016-11-21 아스텔라스세이야쿠 가부시키가이샤 치환 아미드 화합물
ES2682303T3 (es) 2010-08-05 2018-09-19 Zoetis Services Llc Derivados de isoxazolina como agentes antiparasitarios
TW201305178A (zh) 2010-10-29 2013-02-01 Glenmark Pharmaceuticals Sa 作為mPGES-1抑制物的三環化合物
DK2648726T3 (da) 2010-12-07 2018-07-16 Amira Pharmaceuticals Inc Polycyklisk lpa1-antagonist og anvendelser deraf
JP6097998B2 (ja) 2010-12-16 2017-03-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成のビアリールアミドインヒビター
PH12013501831B1 (en) 2011-03-10 2019-06-14 Zoetis Services Llc Spirocyclic isoxazoline derivatives as antiparasitic agents
CA2859965A1 (en) 2011-12-21 2013-06-27 Ardelyx, Inc. Non-systemic tgr5 agonists
WO2014079805A1 (en) 2012-11-23 2014-05-30 Boehringer Ingelheim International Gmbh Pyrazole compounds for treating hairloss
EP2970200A1 (en) * 2013-03-13 2016-01-20 Abbvie Inc. Pyridine cdk9 kinase inhibitors
ES2693718T3 (es) 2013-11-06 2018-12-13 Bristol-Myers Squibb Company Derivados de piridina sustituidos útiles como inhibidores de GSK-3
AR108185A1 (es) 2016-04-06 2018-07-25 Abbvie Inc Amidas terciarias y método para su uso
PT3802517T (pt) 2018-06-07 2023-03-20 Idorsia Pharmaceuticals Ltd Derivados de piridinilo substituídos por alcoxi como antagonistas do recetor de lpa1 e a sua utilização no tratamento da fibrose
JP7665619B2 (ja) 2019-12-04 2025-04-21 イドルシア・ファーマシューティカルズ・リミテッド 線維性疾患の治療に使用するためのアゼチジンlpa1受容体アンタゴニストのピルフェニドン及び/又はニンテダニブとの合剤

Also Published As

Publication number Publication date
WO2020254408A1 (en) 2020-12-24
CN114026082B (zh) 2024-06-07
CA3143618A1 (en) 2020-12-24
IL288950B1 (en) 2024-11-01
IL288950B2 (en) 2025-03-01
CN114026082A (zh) 2022-02-08
AR119162A1 (es) 2021-12-01
KR20220020921A (ko) 2022-02-21
TWI845708B (zh) 2024-06-21
MX2021015727A (es) 2022-01-24
CL2021003348A1 (es) 2022-09-23
KR102786045B1 (ko) 2025-03-24
UA130692C2 (uk) 2026-04-22
PH12021553178A1 (en) 2022-11-07
JP7494222B2 (ja) 2024-06-03
IL288950A (en) 2022-02-01
MA56504A (fr) 2022-04-27
BR112021025236A2 (pt) 2022-02-01
EP3986884A1 (en) 2022-04-27
US20220251068A1 (en) 2022-08-11
JP2022537177A (ja) 2022-08-24
AU2020298014A1 (en) 2022-02-10
US12479820B2 (en) 2025-11-25
AU2020298014B2 (en) 2026-02-05
TW202115011A (zh) 2021-04-16

Similar Documents

Publication Publication Date Title
MX2011008308A (es) Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica.
EP3204383A1 (en) Spirodiamine derivatives as aldosterone synthase inhibitors
JP5530438B2 (ja) Mc4作動薬としてのジアゼピンおよびジアゾカン化合物
AU2014234907B2 (en) Geminally substituted cyanoethylpyrazolo pyridones as Janus kinase inhibitors
EP2976341A1 (en) Acyclic cyanoethylpyrazolo pyridones as janus kinase inhibitors
AU2020298014B2 (en) Pyridin-3-yl derivatives
EP3802517B1 (en) Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis
CN105189497A (zh) 作为janus激酶抑制剂的n-(2-氰基杂环基)吡唑并吡啶酮
WO2020120994A1 (en) Orexin 1 receptor antagonists
EA047605B1 (ru) Пиридин-3-ильные производные
US12240825B2 (en) Oxexin 1 receptor antagonists
HK40066271A (zh) 吡啶-3-基衍生物
HK40066271B (zh) 吡啶-3-基衍生物
WO2025181828A1 (en) Triamino pyrimidine compounds as cdk7 inhibitors and methods thereof